阿替利珠单抗致4级免疫检查点抑制剂相关性肺炎死亡1例

One death case report of gradeⅣcheckpoint inhibitor pneumonitis induced by atezolizumab

阿替利珠单抗是一种人源化单克隆抗体,随着阿替利珠单抗临床广泛使用,免疫相关不良事件报道逐渐增加。阿替利珠单抗致免疫检查点抑制剂相关性肺炎(checkpoint inhibitor pneumonitis,CIP)是一种罕见的危及生命的不良事件,国内尚无病例报告。该文报道并分析了1例使用阿替利珠单抗5个月后出现CIP的肾癌患者,以期提高临床医师对阿替利珠单抗相关不良反应的认识。

Attillizumab is a humanized monoclonal anti-body.With its widespread clinical application,there are grow-ing reports of immune-related adverse events.Checkpoint inhibitor pneumonitis(CIP)induced by attilizumab is a rare life-threatening adverse event.It has never been reported in China.Here we described and analysis an onset of CIP in a renal cancer patient after a 5-month therapy of attilizumab to enhance clinicians'understanding of its adverse effects.